Supernus Pharmaceuticals, Inc. (SUPN) Position Reduced by Essex Investment Management Co. LLC

Essex Investment Management Co. LLC lessened its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 17.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 63,244 shares of the specialty pharmaceutical company’s stock after selling 13,535 shares during the quarter. Essex Investment Management Co. LLC owned about 0.12% of Supernus Pharmaceuticals worth $2,530,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Mesirow Financial Investment Management Equity Management boosted its position in shares of Supernus Pharmaceuticals by 66.8% during the third quarter. Mesirow Financial Investment Management Equity Management now owns 354,955 shares of the specialty pharmaceutical company’s stock worth $14,200,000 after buying an additional 142,215 shares during the period. Rosenblum Silverman Sutton S F Inc. CA acquired a new position in Supernus Pharmaceuticals during the third quarter valued at approximately $288,000. Crossmark Global Holdings Inc. acquired a new position in Supernus Pharmaceuticals during the third quarter valued at approximately $858,000. Pictet Asset Management Ltd. lifted its position in shares of Supernus Pharmaceuticals by 438.7% in the third quarter. Pictet Asset Management Ltd. now owns 491,283 shares of the specialty pharmaceutical company’s stock valued at $19,651,000 after buying an additional 400,083 shares during the last quarter. Finally, First Trust Advisors LP acquired a new stake in shares of Supernus Pharmaceuticals in the third quarter valued at approximately $2,255,000. Institutional investors own 95.06% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.com-unik.info/2017/11/03/supernus-pharmaceuticals-inc-supn-position-reduced-by-essex-investment-management-co-llc.html.

In other news, insider Stefan K.F. Schwabe sold 95,000 shares of the business’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $46.59, for a total value of $4,426,050.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Padmanabh P. Bhatt sold 5,000 shares of the business’s stock in a transaction dated Friday, September 8th. The stock was sold at an average price of $49.86, for a total transaction of $249,300.00. Following the completion of the sale, the senior vice president now owns 12,500 shares in the company, valued at $623,250. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 153,709 shares of company stock worth $7,223,108. 6.70% of the stock is owned by corporate insiders.

A number of equities analysts have recently weighed in on the company. BidaskClub upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 17th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $49.00 target price on shares of Supernus Pharmaceuticals in a report on Tuesday, September 19th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $47.00 target price (up previously from $36.00) on shares of Supernus Pharmaceuticals in a report on Tuesday, July 18th. Jefferies Group LLC reissued a “buy” rating and set a $51.00 price objective on shares of Supernus Pharmaceuticals in a report on Friday, August 4th. Finally, Zacks Investment Research raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 price objective on the stock in a report on Thursday, July 13th. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Supernus Pharmaceuticals has an average rating of “Buy” and an average price target of $48.38.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.08. The business had revenue of $75.83 million for the quarter, compared to analysts’ expectations of $68.54 million. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

What are top analysts saying about Supernus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Supernus Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit